Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ramsdens shares shine as outlook lifted on surging gold price

(Sharecast News) - Shares in Ramsdens shone on Tuesday as the pawnbroker lifted its full-year profit outlook on the back of surging gold prices. The company, which buys jewellery or gold from customers and then sells it on to individuals or bullion dealers, said it now expected annual pre-tax profits of £13m for fiscal 2025 compared with the £11.4m previously forecast by analysts.

Gold prices have hit record highs above $3,000 an ounce as investors seek safe havens in response to US President Donald Trump's plan to hammer all trading partners with import tariffs, sending equity and bond markets into turmoil.

In a first-half trading update, Ramsdens said its precious metals segment had continued to perform very strongly with gross profit increasing 50% year on year.

"This has been driven by the continued high gold price, coupled with a 5% increase in the weight of gold purchased. The group launched its dedicated gold buying website in March 2025 which is expected to increase awareness of this service and attract new customers," the company said.

Jewellery retail gross profit rose 15%, ahead of expectations and despite the scrapping of some aged stock. Its pawnbroking service - where people can take out a loan against the value of a piece of jewellery or a watch - reported a 10% increase in gross profits.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.